[go: up one dir, main page]

LUC00031I2 - - Google Patents

Info

Publication number
LUC00031I2
LUC00031I2 LU00031C LUC00031C LUC00031I2 LU C00031 I2 LUC00031 I2 LU C00031I2 LU 00031 C LU00031 C LU 00031C LU C00031 C LUC00031 C LU C00031C LU C00031 I2 LUC00031 I2 LU C00031I2
Authority
LU
Luxembourg
Application number
LU00031C
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of LUC00031I1 publication Critical patent/LUC00031I1/fr
Publication of LUC00031I2 publication Critical patent/LUC00031I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU00031C 2001-05-31 2017-08-09 LUC00031I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06
EP02733058A EP1392694A1 (fr) 2001-05-31 2002-05-29 Resolution optique de (1-benzyl-4-methylpiperidine-3-yle) methylamine et son utilisation pour la preparation de derives de pyrrolo 2,3-pyrimidine utilises comme inhibiteurs de proteines kinase

Publications (2)

Publication Number Publication Date
LUC00031I1 LUC00031I1 (fr) 2017-08-10
LUC00031I2 true LUC00031I2 (fr) 2017-10-11

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00031C LUC00031I2 (fr) 2001-05-31 2017-08-09

Country Status (52)

Country Link
US (2) US7301023B2 (fr)
EP (3) EP1392694A1 (fr)
JP (1) JP4381137B2 (fr)
KR (5) KR20060133117A (fr)
CN (1) CN1729192A (fr)
AP (1) AP1859A (fr)
AR (2) AR037321A1 (fr)
AT (1) ATE519741T1 (fr)
AU (2) AU2002304401C1 (fr)
BE (1) BE2017C032I2 (fr)
BG (1) BG66489B1 (fr)
BR (1) BR0209246A (fr)
CA (1) CA2448281C (fr)
CL (1) CL2008000762A1 (fr)
CR (1) CR10177A (fr)
CU (1) CU23337B7 (fr)
CY (2) CY1113322T1 (fr)
CZ (1) CZ304366B6 (fr)
DK (1) DK1666481T3 (fr)
EA (2) EA012666B1 (fr)
EC (1) ECSP034865A (fr)
EE (1) EE05332B1 (fr)
ES (2) ES2393385T3 (fr)
FR (1) FR17C1031I2 (fr)
GE (1) GEP20063784B (fr)
GT (2) GT200200100AA (fr)
HR (1) HRP20030943B1 (fr)
HU (2) HU230876B1 (fr)
IL (1) IL158588A0 (fr)
IS (1) IS3023B (fr)
LT (1) LTC1666481I2 (fr)
LU (1) LUC00031I2 (fr)
MA (1) MA27029A1 (fr)
MX (1) MXPA03011062A (fr)
MY (1) MY129649A (fr)
NL (1) NL300887I2 (fr)
NO (3) NO328578B1 (fr)
NZ (2) NZ530380A (fr)
OA (1) OA12612A (fr)
PA (1) PA8546301A1 (fr)
PE (1) PE20030561A1 (fr)
PL (2) PL228155B1 (fr)
PT (1) PT1666481E (fr)
RS (1) RS52144B (fr)
SI (1) SI1666481T1 (fr)
SK (2) SK288192B6 (fr)
TN (1) TNSN03128A1 (fr)
TW (2) TWI316061B (fr)
UA (1) UA80093C2 (fr)
UY (1) UY27317A1 (fr)
WO (1) WO2002096909A1 (fr)
ZA (1) ZA200307982B (fr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
DK1382339T3 (da) * 1999-12-10 2008-01-28 Pfizer Prod Inc Kompositioner indeholdende pyrrolo 2,3-d pyrimidinderivater
CA2412560C (fr) * 2000-06-26 2008-12-30 Pfizer Products Inc. Composes pyrrolo[2,3-d]pyrimidine en tant qu'agents immunosuppresseurs
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE60330466D1 (de) 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
US7476683B2 (en) * 2002-08-27 2009-01-13 Merck Patent Gmbh Glycinamide derivatives as raf-kinase inhibitors
WO2004047843A1 (fr) 2002-11-26 2004-06-10 Pfizer Products Inc. Methode de traitement d'un rejet de greffe
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
EP1755680A1 (fr) * 2004-05-03 2007-02-28 Novartis AG Combinaisons comprenant un agoniste du recepteur s1p et un inhibiteur de la kinase jak3
AU2005260032A1 (en) 2004-06-29 2006-01-12 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
KR20070085433A (ko) * 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
EP2251341A1 (fr) 2005-07-14 2010-11-17 Astellas Pharma Inc. Hétérocycles inhibiteurs de Janus kinase-3
BRPI0613876A2 (pt) 2005-07-29 2011-02-15 Pfizer Prod Inc derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese
WO2007038215A1 (fr) 2005-09-22 2007-04-05 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
ES2543904T3 (es) 2005-12-13 2015-08-25 Incyte Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
EP1991532B1 (fr) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions et méthodes destinées à l'inhibition de la voie jak
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
CA2673038C (fr) 2006-12-22 2015-12-15 Incyte Corporation Composes heteroaryls tricycliques substitues comme inhibiteurs de kinase janus
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP4011883A1 (fr) 2007-06-13 2022-06-15 Incyte Holdings Corporation Sels de l'inhibiteur de janus kinase (r)-3-(4-(7h-pyrrolo[2,3-d -1h-]pyrimidine-4-yl) -1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2008273804B2 (en) * 2007-07-11 2014-07-10 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
CN102007124B (zh) 2008-02-15 2014-06-18 里格尔制药公司 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
TWI444382B (zh) 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
US20110165183A1 (en) * 2008-08-01 2011-07-07 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
PL2384326T3 (pl) 2008-08-20 2014-09-30 Zoetis Services Llc Związki pirolo[2,3-d]pirymidyonowe
EP2396004A4 (fr) * 2009-02-11 2012-07-25 Reaction Biology Corp Inhibiteurs de kinase sélectifs
CA3025627C (fr) * 2009-04-20 2021-08-31 Auspex Pharmaceuticals, Inc. Inhibiteurs piperidiniques de la janus kinase 3
WO2010135650A1 (fr) 2009-05-22 2010-11-25 Incyte Corporation Dérivés de n-(hétéro)aryl-pyrrolidine de pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines et pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines en tant qu'inhibiteurs de la janus kinase
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
RU2538204C2 (ru) * 2009-09-10 2015-01-10 Ф.Хоффманн-Ля Рош Аг Ингибиторы jak
WO2011044481A1 (fr) 2009-10-09 2011-04-14 Incyte Corporation Dérivés hydroxy, céto et glucuronides de 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylpropanenitrile
AP2012006192A0 (en) 2009-10-15 2012-04-30 Pfizer PyrroloÄ2,3-DÜ pyrimidine compounds.
CA2782720A1 (fr) 2009-12-18 2011-06-23 Pfizer Inc. Composes pyrrolo[2,3-d]pyrimidines
EP2523957A1 (fr) * 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Composés hétérocycliques tricycliques, leurs compositions et procédés d'utilisation
MX2012009074A (es) 2010-02-05 2012-08-23 Pfizer Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
NZ602313A (en) 2010-03-10 2014-08-29 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
EP2635557A2 (fr) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides en tant que modulateurs des jak kinases
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
EP2481411A1 (fr) 2011-01-27 2012-08-01 Ratiopharm GmbH Formes galéniques orales pour libération modifiée comportant l'inhibiteur de JAK3 tasocitinib
EP2481397A1 (fr) 2011-01-27 2012-08-01 Ratiopharm GmbH Compositions pharmaceutiques comportant du tasocitinib
PT2675451E (pt) 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
WO2012135338A1 (fr) 2011-03-28 2012-10-04 Ratiopharm Gmbh Procédés pour la préparation de sels de tofacitinib
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
CA2830463A1 (fr) * 2011-04-08 2012-10-11 Pfizer Inc. Composition pharmaceutique renfermant du tofacitinib et un agent d'amelioration de la penetration
EP2524688B1 (fr) 2011-05-11 2013-05-01 ratiopharm GmbH Composition de libération modifiée comportant de la ranolazine
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013078466A1 (fr) 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Inhibiteurs de de la pyrazine kinase
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
CA3131037A1 (fr) 2011-11-30 2013-06-06 Emory University Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales
EP3170826A1 (fr) 2011-12-15 2017-05-24 ratiopharm GmbH Sel de mono-malate de tofacitinib
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2014016338A1 (fr) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. Nouvelle voie de synthèse pour la préparation de composés 3-amino-pipéridine
EP2903970A4 (fr) 2012-10-08 2016-11-30 Portola Pharm Inc Inhibiteurs substitués de pyrimidinyl kinase
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
CN104955803B (zh) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
WO2014097150A1 (fr) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Procédé de préparation de tofacitinib et de ses intermédiaires
EP2938616A4 (fr) 2012-12-28 2016-06-15 Glenmark Pharmaceuticals Ltd Procédé de préparation de tofacitinib et d'intermédiaires
HUE041778T2 (hu) 2013-02-22 2019-05-28 Pfizer Pirrolo[2,3-d]pirimidin-származékok és egy vagy több további szer kombinációja Janus-típusú kinázok (JAK) gátlóiként
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (fr) 2013-04-26 2014-10-30 Sandoz Ag Formulations de tofacitinib à libération prolongée
CN116036089A (zh) 2013-08-07 2023-05-02 因赛特控股公司 Jak1抑制剂的持续释放剂型
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
PL3318565T3 (pl) 2013-12-05 2021-10-04 Pfizer Inc. Pirolo[2,3-d]pirymidynylowe, pirolo[2,3-b]pirazynylowe i pirolo[2,3-d]pirydynylowe akryloamidy
ES2720066T3 (es) 2013-12-09 2019-07-17 Unichem Lab Ltd Mejora del proceso de preparación de (3R,4R)-(1-bencil-4-metilpiperidín-3-il)-metilamina
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
EP3180344B1 (fr) 2014-08-12 2019-09-18 Pfizer Inc Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
PL3248980T3 (pl) * 2015-01-20 2024-03-04 Wuxi Fortune Pharmaceutical Co., Ltd Inhibitor jak
CN106660949B (zh) * 2015-02-17 2020-11-13 株式会社爱茉莉太平洋 N-[4-(1-氨基乙基)-苯基]-磺酰胺衍生物的手性拆分方法
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (fr) 2015-04-10 2016-10-12 OLON S.p.A. Procédé efficace pour la préparation de tofacitinib citrate
HUE044240T2 (hu) 2015-04-29 2019-10-28 Wuxi Fortune Pharmaceutical Co Ltd Janus kináz (JAK) inhibitorok
WO2016178110A1 (fr) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo [2,3-d] pyrimidinyl, pyrrolo[2,3-b] pyrazinyl, pyrrolo [2,3-b] pyridinyl acrylamides et leur époxydes
KR102081272B1 (ko) 2015-05-29 2020-02-25 우시 포춘 파마슈티컬 컴퍼니 리미티드 Janus 키나아제 억제제
KR101964546B1 (ko) * 2015-07-27 2019-04-01 유니켐 레버러토리스 리미티드 토파시티닙 경구 붕해 정제
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
WO2017125417A1 (fr) 2016-01-18 2017-07-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Tofacitinib comme immunomodulateur de vaccination
JP2019519579A (ja) 2016-06-30 2019-07-11 デウン ファーマシューティカル カンパニー リミテッド キナーゼ阻害剤としてのピラゾロピリミジン誘導体
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
BR112020013141B1 (pt) 2017-12-28 2022-03-15 Daewoong Pharmaceutical Co., Ltd Compostos de óxi-fluoropiperidina como inibidores de quinase, composição farmacêutica compreendendo os mesmos e seu uso na prevenção ou no tratamento de doenças inflamatórias, doenças autoimunes, doenças proliferativas ou doenças hiperproliferativas e doenças imunomediadas, cânceres, tumores
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CR20200379A (es) 2018-01-30 2021-03-05 Incyte Corp Procesos e intermedio para elaborar un inhibidor de jak campo técnico
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
BR112020015688A8 (pt) * 2018-01-31 2022-07-05 Twi Pharmaceuticals Inc Formulações tópicas que compreendem tofacitinibe
AU2019245420B2 (en) 2018-03-30 2024-10-10 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
US20220153743A1 (en) 2019-03-13 2022-05-19 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
EP3946606B1 (fr) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Inhibiteurs de jak bicycliques et leurs utilisations
WO2020204647A1 (fr) * 2019-04-05 2020-10-08 Yuhan Corporation Procédés de préparation de (3r,4r)-1-benzyl-n,4-diméthylpipéridin-3-amine ou d'un sel de celui-ci et procédés de préparation de tofacitinib l'utilisant
BR112022007826A2 (pt) 2019-11-14 2022-07-05 Pfizer Combinações de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il)metóxi)-7-metóxi-isoquino¬lina-6-carboxamida e formas de dosagem oral
EP4067354A4 (fr) 2019-11-25 2023-11-08 Daewoong Pharmaceutical Co., Ltd. Nouveau dérivé de triazolopyridine et composition pharmaceutique le comprenant
US20230149407A1 (en) 2020-04-04 2023-05-18 Pfizer Inc. Methods of Treating Coronavirus Disease 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022194782A1 (fr) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Dérivés hétérocycliques utilisés en tant qu'inhibiteurs de janus kinase
EP4180042A1 (fr) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé enrobé d'un film comprenant du tofacitinib micronisé

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
WO1996040142A1 (fr) 1995-06-07 1996-12-19 Pfizer Inc. Derives de pyrimidine heterocycliques a noyaux condenses
CN1105113C (zh) 1995-07-05 2003-04-09 纳幕尔杜邦公司 杀真菌嘧啶酮
CN1100778C (zh) 1995-07-06 2003-02-05 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
IL121090A0 (en) 1995-11-14 1997-11-20 Pharmacia & Upjohn Spa Aryl and heteroaryl purine compounds
WO1997027199A1 (fr) 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0912572B1 (fr) 1996-07-13 2003-01-15 Glaxo Group Limited Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
DK0938486T3 (da) 1996-08-23 2008-07-07 Novartis Ag Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
EP0946554A1 (fr) 1996-11-27 1999-10-06 Pfizer Inc. Derives de pyrimidines bicycliques fusionnes
AU749750B2 (en) 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
JP2001520748A (ja) 1997-03-24 2001-10-30 ファルマシア・アンド・アップジョン・カンパニー Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
AU3378799A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors
CA2333392A1 (fr) 1998-05-28 1999-12-02 Parker Hughes Institute Utilisation des quinazolines pour le traitement de tumeurs cerebrales
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1087970B1 (fr) * 1998-06-19 2004-04-28 Pfizer Products Inc. COMPOSES DE PYRROLO 2,3d]PYRIMIDINE
JP2004504259A (ja) 1998-06-30 2004-02-12 パーカー　ヒューズ　インスティテュート Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
JP2002523403A (ja) 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DK1382339T3 (da) * 1999-12-10 2008-01-28 Pfizer Prod Inc Kompositioner indeholdende pyrrolo 2,3-d pyrimidinderivater
CA2412560C (fr) 2000-06-26 2008-12-30 Pfizer Products Inc. Composes pyrrolo[2,3-d]pyrimidine en tant qu'agents immunosuppresseurs
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
AU2005260032A1 (en) * 2004-06-29 2006-01-12 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity

Also Published As

Publication number Publication date
TWI316061B (en) 2009-10-21
PA8546301A1 (es) 2003-05-14
AP1859A (en) 2008-07-02
KR20080002931A (ko) 2008-01-04
CA2448281C (fr) 2009-05-05
NO20035201L (no) 2003-11-24
LUC00031I1 (fr) 2017-08-10
NO20035201D0 (no) 2003-11-24
HRP20030943B1 (en) 2011-11-30
BG66489B1 (bg) 2015-05-29
AU2002304401C1 (en) 2009-03-05
ES2393385T3 (es) 2012-12-20
ZA200307982B (en) 2004-10-14
GEP20063784B (en) 2006-04-10
HRP20030943A2 (en) 2005-08-31
HUP0400152A2 (en) 2007-07-30
TWI310384B (en) 2009-06-01
GT200200100A (es) 2003-02-11
FR17C1031I2 (fr) 2018-11-02
CZ20033260A3 (en) 2004-03-17
CZ304366B6 (cs) 2014-04-02
FR17C1031I1 (fr) 2017-10-13
NL300887I2 (nl) 2017-08-31
UA80093C2 (uk) 2007-08-27
NO2017047I1 (no) 2017-09-08
CY2017028I2 (el) 2018-02-14
EE05332B1 (et) 2010-08-16
CN1729192A (zh) 2006-02-01
KR20080083028A (ko) 2008-09-12
AU2008203170A1 (en) 2008-08-07
US20030073719A1 (en) 2003-04-17
EE200300594A (et) 2004-04-15
KR20060133117A (ko) 2006-12-22
SI1666481T1 (sl) 2012-11-30
PL367945A1 (en) 2005-03-07
EA200301193A1 (ru) 2004-04-29
MXPA03011062A (es) 2004-03-19
CA2448281A1 (fr) 2002-12-05
CL2008000762A1 (es) 2008-07-04
JP2004534047A (ja) 2004-11-11
EP1666481B1 (fr) 2012-09-19
IL158588A0 (en) 2004-05-12
ECSP034865A (es) 2004-01-28
AU2002304401B2 (en) 2008-04-17
SK288192B6 (sk) 2014-06-03
MY129649A (en) 2007-04-30
RS52144B (en) 2012-08-31
AU2008203170B2 (en) 2009-06-18
PL228155B1 (pl) 2018-02-28
NZ540332A (en) 2007-05-31
KR100869409B1 (ko) 2008-11-21
CY2017028I1 (el) 2018-02-14
IS3023B (is) 2020-08-15
AR037321A1 (es) 2004-11-03
BR0209246A (pt) 2004-06-15
NO20093135L (no) 2003-11-24
BE2017C032I2 (fr) 2021-07-19
LTC1666481I2 (lt) 2018-06-25
OA12612A (en) 2006-06-09
YU92303A (sh) 2006-08-17
KR20060014459A (ko) 2006-02-15
SK288199B6 (sk) 2014-06-03
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
TNSN03128A1 (fr) 2005-12-23
EP1666481A3 (fr) 2006-11-29
BG108389A (bg) 2005-01-31
KR100926875B1 (ko) 2009-11-16
CR10177A (es) 2008-08-19
GT200200100AA (es) 2007-07-06
ATE519741T1 (de) 2011-08-15
SK14652003A3 (sk) 2004-05-04
EP1392694A1 (fr) 2004-03-03
EP1609781B1 (fr) 2011-08-10
IS6993A (is) 2003-10-13
NZ530380A (en) 2005-08-26
DK1666481T3 (da) 2012-10-15
KR20040003037A (ko) 2004-01-07
PL409305A1 (pl) 2014-12-22
US7301023B2 (en) 2007-11-27
EP1666481A2 (fr) 2006-06-07
US20040229923A1 (en) 2004-11-18
HU230876B1 (hu) 2018-11-29
PE20030561A1 (es) 2003-06-23
EA200600575A1 (ru) 2006-08-25
PT1666481E (pt) 2012-12-03
NO328578B1 (no) 2010-03-22
UY27317A1 (es) 2003-02-28
EA007251B1 (ru) 2006-08-25
EP1609781A1 (fr) 2005-12-28
HUS1900008I1 (hu) 2020-02-28
LTPA2017025I1 (lt) 2017-09-11
CU23337B7 (es) 2009-01-20
CY1113322T1 (el) 2016-06-22
ES2369226T3 (es) 2011-11-28
EA012666B1 (ru) 2009-12-30
JP4381137B2 (ja) 2009-12-09
HUP0400152A3 (en) 2012-12-28
TW200413370A (en) 2004-08-01
US7432370B2 (en) 2008-10-07
MA27029A1 (fr) 2004-12-20
KR100868814B1 (ko) 2008-11-14
WO2002096909A1 (fr) 2002-12-05
EP1666481B9 (fr) 2013-05-01

Similar Documents

Publication Publication Date Title
BE2022C531I2 (fr)
BE2022C502I2 (fr)
BE2022C547I2 (fr)
BE2017C059I2 (fr)
BE2017C057I2 (fr)
BE2017C051I2 (fr)
BE2017C032I2 (fr)
BE2016C051I2 (fr)
BE2014C052I2 (fr)
BE2014C036I2 (fr)
BE2014C026I2 (fr)
BE2011C034I2 (fr)
JP2002200814A5 (fr)
JP2001292394A5 (fr)
BE2014C006I2 (fr)
BRPI0209186B1 (fr)
BE2017C050I2 (fr)
BRPI0204884B1 (fr)
BE2014C008I2 (fr)
CH1379220H1 (fr)
BE2016C021I2 (fr)
JP2002064311A5 (fr)
FR11C0013I1 (fr)
BRPI0101486B8 (fr)
JP2001267018A5 (fr)